Incyte Corporation $INCY Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in shares of Incyte Corporation (NASDAQ:INCY) by 54.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 844,389 shares of the biopharmaceutical company’s stock after buying an additional 299,014 shares during the period. Incyte comprises approximately 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings, making the stock its 23rd biggest holding. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Incyte were worth $102,467,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in INCY. Parcion Private Wealth LLC increased its position in shares of Incyte by 3.7% during the third quarter. Parcion Private Wealth LLC now owns 5,839 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 206 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Incyte by 16.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,984 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 5,189 shares in the last quarter. D.A. Davidson & CO. grew its stake in Incyte by 10.1% during the 3rd quarter. D.A. Davidson & CO. now owns 7,743 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 710 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in Incyte by 59.8% during the 3rd quarter. Motley Fool Asset Management LLC now owns 5,258 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 1,967 shares in the last quarter. Finally, Generali Asset Management SPA SGR increased its holdings in Incyte by 6.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 6,508 shares of the biopharmaceutical company’s stock worth $790,000 after purchasing an additional 368 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Truist Financial upped their target price on Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a research report on Wednesday, October 14th. Wall Street Zen downgraded shares of Incyte from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Mizuho raised their price target on shares of Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Wells Fargo & Company dropped their price target on shares of Incyte from $128.00 to $127.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $132.90.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Incyte Stock Performance

Shares of INCY stock opened at $120.39 on Friday. The stock has a market capitalization of $24.40 billion, a price-to-earnings ratio of 64.04, a PEG ratio of 4.83 and a beta of 0.74. Incyte Corporation has a one year low of $89.25 and a one year high of $132.60. The company’s 50-day simple moving average is $120.49 and its 200-day simple moving average is $108.14.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same period in the previous year, the company earned $2.26 earnings per share. Incyte’s quarterly revenue was up 14.0% on a year-over-year basis. As a group, research analysts forecast that Incyte Corporation will post 1.97 EPS for the current year.

Insider Activity at Incyte

In other news, insider Pablo Cagnoni sold 10,801 shares of Incyte stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares in the company, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.